3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
2
Plasma cell
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
5
Breast Neoplasms
3
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Preference
1
Patient Acceptance of Health Care
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
5
trametinib
4
pembrolizumab
4
Trastuzumab
3
Nivolumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
belinostat
2
Surveys and Questionnaires
2
Sunitinib
2
Specimen Handling
2
Radiosurgery
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
spartalizumab
1
sargramostim
1
sapanisertib
1
romidepsin
1
repotrectinib
1
relatlimab
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Focus Groups
×
Gastrointestinal
×
Clear all
NCT06236373
2024-12-09
Survivorship
University of Modena and Reggio Emilia
Recruiting
45 enrolled